Skip to main content
SpringerLink
Log in

CYP2D6-Genotypisierung vor Tamoxifen-Therapiestart

CYP2D6 genotyping prior to starting tamoxifen treatment

  • Arzneimitteltherapiesicherheit
  • Published:
best practice onkologie Aims and scope

An Erratum to this article was published on 09 October 2019

This article has been updated

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Change history

  • 09 October 2019

    Erratum zu:

  • 09 October 2019

    Erratum zu:

Literatur

  1. Barnert A, Jaehde U (2017) Therapietreue in der oralen Tumortherapie. Best Pract Oncol 12:278–284

    Article  Google Scholar 

  2. Binkhorst L, Bannink M, de Bruijn P et al (2016) Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch. Clin Pharmacokinet 55:249–255

    Article  CAS  Google Scholar 

  3. Binkhorst L, van Gelder T, Loos WJ et al (2012) Effects of CYP induction by Rifampicin on Tamoxifen exposure. Clin Pharmacol Ther 92:62–67

    Article  CAS  Google Scholar 

  4. Binkhorst L, Mathijssen RHJ, Jager A, van Gelder T (2015) Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping. Cancer Treat Rev 41:289–299

    Article  CAS  Google Scholar 

  5. Brauch H, Schroth W, Goetz MP et al (2013) Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol 31:176–180

    Article  CAS  Google Scholar 

  6. Desta Z (2004) Comprehensive evaluation of Tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310:1062–1075

    Article  CAS  Google Scholar 

  7. Goetz MP, Sangkuhl K, Guchelaar H‑J et al (2018) Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and Tamoxifen therapy. Clin Pharmacol Ther 103:770–777

    Article  Google Scholar 

  8. Hansten PD (2018) The underrated risks of Tamoxifen drug interactions. Eur J Drug Metab Pharmacokinet 43:495–508

    Article  CAS  Google Scholar 

  9. Harbeck N, Gnant M (2017) Breast cancer. Lancet 389:1134–1150

    Article  Google Scholar 

  10. Jordan VC (2007) Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev Cancer 7:46–53

    Article  CAS  Google Scholar 

  11. Klopp-Schulze L, Joerger M, Wicha SG et al (2018) Exploiting pharmacokinetic models of Tamoxifen and Endoxifen to identify factors causing subtherapeutic concentrations in breast cancer patients. Clin Pharmacokinet 57:229–242

    Article  CAS  Google Scholar 

  12. Madlensky L, Natarajan L, Tchu S et al (2011) Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 89:718–725

    Article  CAS  Google Scholar 

  13. Mürdter TE, Schroth W, Bacchus-Gerybadze L et al (2011) Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 89:708–717

    Article  Google Scholar 

  14. Saladores P, Mürdter T, Eccles D et al (2014) Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer. Pharmacogenomics J 15:84–94

    Article  Google Scholar 

  15. Sihinevich I, Ortland I, Jaehde U (2016) Individuelle Dosisanpassung durch Therapeutisches Drug Monitoring. Best Pract Oncol 11:38–42

    Article  Google Scholar 

  16. Wicha SG, Kees MG, Solms A et al (2015) TDMx: A novel web-based open-access support tool for optimising antimicrobial dosing regimens in clinical routine. Int J Antimicrob Agents 45:442–444

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abt. Klinische Pharmazie und Biochemie, Institut für Pharmazie, Freie Universität Berlin, Kelchstraße 31, 12169, Berlin, Deutschland

    Charlotte Kloft

Authors
  1. Charlotte Kloft
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charlotte Kloft.

Ethics declarations

Interessenkonflikt

L. Klopp-Schulze steht in einem Beschäftigungsverhältnis mit Fa. Merck KGaA. C. Kloft erhielt Forschungsunterstützungen von einem Industriekonsortium (Fa. AbbVie Deutschland GmbH & Co. KG, Fa. Boehringer Ingelheim Pharma GmbH & Co. KG, Fa. Grünenthal GmbH, Fa. F. Hoffmann-La Roche Ltd, Fa. Merck KGaA und Fa. Sanofi), der Innovative Medicines Initiative Joint Undertaking (DDMoRe) und Fa. Diurnal Ltd.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren. Für die zitierten Studien gelten die jeweils dort aufgeführten ethischen Richtlinien.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kloft, C. CYP2D6-Genotypisierung vor Tamoxifen-Therapiestart. best practice onkologie 13, 325–329 (2018). https://doi.org/10.1007/s11654-018-0102-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-018-0102-x

Search

Navigation